As drug development becomes increasingly expensive and complex, pharma companies are relying on the services of contract development and manufacturing organizations (CDMOs) to aid them in the creation and commercialization of their products. This practice allows firms to reserve precious resource for business growth activities, while CDMO partners with extensive experience and expertise can focus on the development and production of their pipelines.

With varied strategies for pharma companies to assess, Pharma Intelligence conducted a survey in partnership with Cambrex considering the opportunities and challenges of end-to-end arrangements. Download the full report below.